Shennan M G, Badin A C, Walsh S, Summers A, From L, McKenzie M, Goldstein A M, Tucker M A, Hogg D, Lassam N
Department of Medicine, University of Toronto, Ontario, Canada.
Oncogene. 2000 Mar 30;19(14):1849-52. doi: 10.1038/sj.onc.1203507.
Germline mutations in genes encoding several components of the retinoblastoma pathway have been linked with inherited predisposition to melanoma. Most commonly, such mutations involve CDKN2A, a cyclin-dependent kinase inhibitor of two kinases, CDK4 and CDK6, which phosphorylate the retinoblastoma protein (pRB) and thereby promote passage through the G1/S cell-cycle restriction point. Less frequently, germline mutations in the CDK4 gene have also been linked with an increased risk of melanoma. Despite the sequence and functional homology between CDK4 and CDK6, the role of germline mutations in CDK6 in melanoma predisposition is unknown. We detected no CDK6 mutations within the p16 (CDKN2A) binding domain in index cases from 60 melanoma-prone kindreds that lacked germline mutations in the coding regions of either CDKN2A or within the entire CDK4 coding region. We conclude that germline mutations in CDK6 do not make a significant contribution to melanoma predisposition.
编码视网膜母细胞瘤通路多个组分的基因中的种系突变已与黑色素瘤的遗传易感性相关联。最常见的是,此类突变涉及CDKN2A,它是两种激酶CDK4和CDK6的细胞周期蛋白依赖性激酶抑制剂,这两种激酶使视网膜母细胞瘤蛋白(pRB)磷酸化,从而促进细胞通过G1/S细胞周期限制点。较少见的是,CDK4基因中的种系突变也与黑色素瘤风险增加有关。尽管CDK4和CDK6之间存在序列和功能同源性,但CDK6种系突变在黑色素瘤易感性中的作用尚不清楚。我们在60个易患黑色素瘤的家族的先证者中,在p16(CDKN2A)结合域内未检测到CDK6突变,这些家族在CDKN2A编码区或整个CDK4编码区内均不存在种系突变。我们得出结论,CDK6种系突变对黑色素瘤易感性没有显著影响。